Evidence for Minimal Cardiogenic Potential of Stem Cell Antigen 1–Positive Cells in the Adult Mouse Heart
2018; Lippincott Williams & Wilkins; Volume: 138; Issue: 25 Linguagem: Inglês
10.1161/circulationaha.118.035273
ISSN1524-4539
AutoresLauren E. Neidig, Florian Weinberger, Nathan J. Palpant, John Mignone, Amy Martinson, Daniel W. Sorensen, Ingrid Bender, Natsumi Nemoto, Hans Reinecke, Lil Pabon, Jeffery D. Molkentin, Charles E. Murry, Jop H. van Berlo,
Tópico(s)Pancreatic function and diabetes
ResumoHomeCirculationVol. 138, No. 25Evidence for Minimal Cardiogenic Potential of Stem Cell Antigen 1–Positive Cells in the Adult Mouse Heart Open AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessLetterPDF/EPUBEvidence for Minimal Cardiogenic Potential of Stem Cell Antigen 1–Positive Cells in the Adult Mouse Heart Lauren E. Neidig, DVM, Florian Weinberger, MD, Nathan J. Palpant, PhD, John Mignone, MD, PhD, Amy M. Martinson, BS, Daniel W. Sorensen, BS, Ingrid Bender, BS, Natsumi Nemoto, BS, Hans Reinecke, PhD, Lil Pabon, PhD, Jeffery D. Molkentin, PhD, Charles E. Murry, MD, PhD and Jop H. van Berlo, MD, PhD Lauren E. NeidigLauren E. Neidig Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Department of Comparative Medicine (L.E.N), University of Washington, Seattle. *Drs Neidig and Weinberger contributed equally. Search for more papers by this author , Florian WeinbergerFlorian Weinberger Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. F.W. is currently at the Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany. *Drs Neidig and Weinberger contributed equally. Search for more papers by this author , Nathan J. PalpantNathan J. Palpant Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. N.J.P. is currently at the Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. Search for more papers by this author , John MignoneJohn Mignone Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Department of Medicine/Cardiology (J.M., C.E.M.), University of Washington, Seattle. J.M. is currently at the Cardiology Division, Swedish Medical Center, Seattle, WA. Search for more papers by this author , Amy M. MartinsonAmy M. Martinson Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Search for more papers by this author , Daniel W. SorensenDaniel W. Sorensen Stem Cell Institute and Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis (D.W.S., I.B., N.N., J.H.v.B.). Search for more papers by this author , Ingrid BenderIngrid Bender Stem Cell Institute and Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis (D.W.S., I.B., N.N., J.H.v.B.). Search for more papers by this author , Natsumi NemotoNatsumi Nemoto Stem Cell Institute and Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis (D.W.S., I.B., N.N., J.H.v.B.). Search for more papers by this author , Hans ReineckeHans Reinecke Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Search for more papers by this author , Lil PabonLil Pabon Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Search for more papers by this author , Jeffery D. MolkentinJeffery D. Molkentin Department of Pediatrics, Howard Hughes Medical Institute, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, OH (J.D.M.). Search for more papers by this author , Charles E. MurryCharles E. Murry Charles Murry, MD, PhD, Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Brotman Building Room 453, Seattle, WA 98109. Email E-mail Address: [email protected] Department of Pathology (L.E.N., F.W., N.J.P., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Institute for Stem Cell and Regenerative Medicine (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Center for Cardiovascular Biology (L.E.N., F.W., N.J.P., J.M., A.M.M., H.R., L.P., C.E.M.), University of Washington, Seattle. Department of Medicine/Cardiology (J.M., C.E.M.), University of Washington, Seattle. Department of Bioengineering (C.E.M.), University of Washington, Seattle. †Drs Murry and van Berlo contributed equally. Search for more papers by this author and Jop H. van BerloJop H. van Berlo Stem Cell Institute and Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis (D.W.S., I.B., N.N., J.H.v.B.). †Drs Murry and van Berlo contributed equally. Search for more papers by this author Originally published17 Dec 2018https://doi.org/10.1161/CIRCULATIONAHA.118.035273Circulation. 2018;138:2960–2962This article is commented on by the following:Adult Cardiac Stem Cell Concept and the Process of ScienceEditorial, see p 2940De novo cardiomyogenesis is limited to ≈1% per year in the adult mammalian heart.1 Whether newly formed cardiomyocytes are derived from division of pre-existing myocytes or from differentiation of resident cardiac progenitor cells is a topic of debate. Cardiac progenitor cells have been posited as a source of endogenous cardiomyocyte renewal and as cells that can be harvested, expanded in vitro, and delivered therapeutically after infarction. Stem cell antigen 1 (Sca-1), which was initially described as a surface marker of murine hematopoietic stem cells, has been reported to mark resident cardiac progenitor cells,2 and a previous study reported frequent contribution of Sca-1–expressing cells to cardiomyocytes.3 However, the transgenic approach used in this study resulted in more widespread expression than just Sca-1–expressing cells, complicating interpretation of the results.4 Because more recent fate mapping studies questioned the existence of resident cardiac progenitor cells, we aimed to test the hypothesis that endogenous Sca-1–expressing cells are progenitors for cardiomyocytes in vivo under physiological and pathophysiological conditions.We generated a tamoxifen-inducible genetic lineage-tracing Sca-1 mER-Cre-mER knock-in mouse model (Sca-1mCm/+)5 and cross-bred to a Rosa26 tdTomato reporter line (Sca-1mCmR26tdTomato) to assess the fate of cellular descendants of Sca-1–expressing cells in vivo. Adult Sca-1mCmR26tdTomato animals were treated with tamoxifen daily for 7 days, and hearts were harvested 7 days after the last tamoxifen injection to assess recombination. Recombination in the heart averaged 33% in Sca-1+/CD31+ populations and 13% in the Sca-1+/CD31– population (Figure [A] and [B]). No tdTomato+ cells were identified by flow cytometry in Sca-1mCmR26dTomato mice that did not receive tamoxifen. Histology (Figure [C]) demonstrated a mostly endothelial expression pattern in Sca-1mCmR26dTomato hearts that colocalized with CD31 expression. Additionally, there was overlap between Sca-1 and tdTomato staining as expected, as well as some NG2-expressing perivascular cells that overlapped with tdTomato. In tissue sections, TdTomato was not identified in cardiomyocytes. Additionally, tamoxifen-dependent tdTomato expression in tissues known to express Sca-1 (kidney, lung, liver, ileum) confirmed the presence of tdTomato+ cells, predominately in an endothelial pattern; this was absent in tissue from animals that received no tamoxifen (data not shown).Download figureDownload PowerPointFigure. Lineage tracing of Sca-1 expressing cells in the mouse heart. A, Stem cell antigen 1 (Sca-1)+CD31+ cells isolated from Sca-1mCmR26tdTomato hearts demonstrated successful recombination after tamoxifen induction (right) without leakiness in the absence of tamoxifen (left). B, Sca-1+CD31− cells isolated from Sca-1mCmR26tdTomato hearts demonstrated successful recombination after tamoxifen induction (right) without leakiness in the absence of tamoxifen (left). C, TdTomato expression demonstrated a vascular staining pattern that overlapped with Sca-1 and CD31 staining. tdTomato expression sometimes overlapped with the perivascular marker NG2, as illustrated by the asterisks. tdTomato expression did not overlap with the cardiomyocyte marker MLC2V. Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). D, Enzymatic digestion allowed for unambiguous differentiation between cardiomyocytes and nonmyocytes. The asterisk indicates a tdTomato+ nonmyocyte in the top panel, whereas the cardiac troponin T (cTnT)+ myocyte in the same image is tdTomato-negative. The bottom panel is an example of a rare tdTomato+ cardiomyocyte. E, Quantification of tdTomato+ cardiomyocytes 7 days after tamoxifen from live cardiomyocytes. F, After myocardial infarction (MI), a total of 19 tdTomato+ cardiomyocytes were detected in 7 animals, accounting for a derived average percentage of 0.007% Sca-1+–derived cardiomyocytes (error bar = SEM). No tdTomato+ cardiomyocytes were observed in the absence of tamoxifen treatment. FSC-A indicates forward-scatter area.Next, we set out to test whether new cardiomyocytes were derived from descendants of Sca-1–expressing cells after myocardial infarction (MI). Adult Sca-1mCmR26dTomato mice were treated with tamoxifen daily for 7 days, followed by a 7-day chase period. The mice then underwent MI or were allowed to age normally. Mice were euthanized 6 months later for examination of the heart. We enzymatically dissociated cardiomyocytes and quantified either fraction of tdTomato+ cardiomyocytes from live cells (uninjured), or after immunostaining for cardiac troponin T and tdTomato (post-MI). This allowed unambiguous distinction of cardiomyocytes and nonmyocytes (Figure [D]). We first assessed the numbers of tdTomato+ cardiomyocytes at baseline before injury and detected 6 tdTomato+ cardiomyocytes from 5 hearts (0.0002%; Figure [E]). We then assessed labeling of cardiomyocytes after MI and detected a total of only 19 tdTomato+ cardiomyocytes from 7 hearts (Figure [F]). This accounts for 0.007% tdTomato+ cardiomyocytes after infarction on average. Importantly, not a single cardiomyocyte expressed tdTomato in animals that were not exposed to tamoxifen, demonstrating that this is not a leaky tracing system.The results of this study do not support the hypothesis that Sca-1–expressing cells have the ability to significantly contribute new cardiomyocytes to the heart after MI in the mouse. Despite using the best available techniques for lineage tracing, including knocking a tamoxifen-inducible Cre recombinase into the endogenous Sca-1 gene, using a sensitive Cre-reporter strain, and enzymatically dispersing cardiomyocytes for single-cell screening, we were unable to detect significant contributions of the Sca-1 lineage to cardiomyocytes.Our study contrasts the study by Uchida et al,3 which showed a significant contribution of Sca-1+ cells to cardiomyocytes. The main difference between these 2 studies relates to the lineage-tracing approach (ie, a transgenic promoter fragment [Uchida et al] versus the endogenous Sca-1 locus dependent Cre expression [this study]). The transgenic system used by Uchida et al has been reported to generate a large number of false-positives, meaning the promoter fragment is active in cells that normally do not express Sca-1.4 Therefore, we believe the transgenic promoter fragment may have overestimated the true cardiogenic potential of endogenous Sca-1–expressing cells in this model. In our model, the recombination rates in the heart were reasonable, but still only resulted in 0.007% of cardiomyocytes to become labeled after MI. Thus, although this number might be an underestimation, it is 2 orders of magnitude too low to explain a 1% per year cardiomyocyte turnover rate. When coupled with data demonstrating that most cardiomyocyte renewal can be accounted for by division of pre-existing cardiomyocytes, our findings reduce the likelihood that there is a cardiac progenitor cell population in mammalian species.All animal procedures complied with and were approved by the Institutional Animal Care and Use Committee.AcknowledgmentsWe thank Dr Kyohei Oyamaya for expert training in cardiomyocyte isolation, and Dr Dale Hailey in the Mike and Lynn Garvey Imaging Core within the Institute for Stem Cell and Regenerative Medicine for assistance with fluorescent imaging.Sources of FundingThis study was supported in part by a grant from the Fondation Leducq Transatlantic Network of Excellence and National Institutes of Health grants P01HL094374, R01HL128362, GM081619 (to C.E.M.), R00HL112852, and R01HL130072 (to J.H.v.B.), and a research scholarship from the German Research Foundation (to F.W.). D.W.S. is supported by National Institutes of Health grant T32GM113846. This research also was supported by the Cell Analysis Facility Flow Cytometry and Imaging Core in the Department of Immunology at the University of Washington.DisclosuresDr Murry is a scientific founder and equity holder in Cytocardia. The other authors report no conflicts.Footnotes*Drs Neidig and Weinberger contributed equally.†Drs Murry and van Berlo contributed equally.Data sharing: Full methodology and validation of genetic approach is available on request and in bioRxiv (https://doi.org/10.1101/404038).https://www.ahajournals.org/journal/circCharles Murry, MD, PhD, Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Brotman Building Room 453, Seattle, WA 98109. Email [email protected]eduReferences1. Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J, Giacca M, Hare JM, Houser S, Lee RT, Marbán E, Martin JF, Molkentin JD, Murry CE, Riley PR, Ruiz-Lozano P, Sadek HA, Sussman MA, Hill JA. Cardiomyocyte regeneration: a consensus statement.Circulation. 2017; 136:680–686. doi: 10.1161/CIRCULATIONAHA.117.029343LinkGoogle Scholar2. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction.Proc Natl Acad Sci U S A. 2003; 100:12313–12318. doi: 10.1073/pnas.2132126100CrossrefMedlineGoogle Scholar3. Uchida S, De Gaspari P, Kostin S, Jenniches K, Kilic A, Izumiya Y, Shiojima I, Grosse Kreymborg K, Renz H, Walsh K, Braun T. Sca1-derived cells are a source of myocardial renewal in the murine adult heart.Stem Cell Reports. 2013; 1:397–410. doi: 10.1016/j.stemcr.2013.09.004CrossrefMedlineGoogle Scholar4. Ma X, Robin C, Ottersbach K, Dzierzak E. The Ly-6A (Sca-1) GFP transgene is expressed in all adult mouse hematopoietic stem cells.Stem Cells. 2002; 20:514–521. doi: 10.1634/stemcells.20-6-514CrossrefMedlineGoogle Scholar5. Hanson P, Mathews V, Marrus SH, Graubert TA. Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo.Exp Hematol. 2003; 31:159–167.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Correia M, Santos F, da Silva Ferreira R, Ferreira R, Bernardes de Jesus B and Nóbrega-Pereira S (2022) Metabolic Determinants in Cardiomyocyte Function and Heart Regenerative Strategies, Metabolites, 10.3390/metabo12060500, 12:6, (500) Wang J, Gu S, Liu F, Chen Z, Xu H, Liu Z, Cheng W, Wu L, Xu T, Chen Z, Chen D, Chen X, Zeng F, Zhao Z, Zhang M and Cao N (2022) Reprogramming of fibroblasts into expandable cardiovascular progenitor cells via small molecules in xeno-free conditions, Nature Biomedical Engineering, 10.1038/s41551-022-00865-7, 6:4, (403-420), Online publication date: 1-Apr-2022. Garbern J and Lee R (2022) Heart regeneration: 20 years of progress and renewed optimism, Developmental Cell, 10.1016/j.devcel.2022.01.012, 57:4, (424-439), Online publication date: 1-Feb-2022. Scalise M, Marino F, Salerno L, Mancuso T, Cappetta D, Barone A, Parrotta E, Torella A, Palumbo D, Veltri P, De Angelis A, Berrino L, Rossi F, Weisz A, Rota M, Urbanek K, Nadal-Ginard B, Torella D and Cianflone E (2021) In vitro CSC-derived cardiomyocytes exhibit the typical microRNA-mRNA blueprint of endogenous cardiomyocytes, Communications Biology, 10.1038/s42003-021-02677-y, 4:1, Online publication date: 1-Dec-2021. Wang Y, Chen J, Cowan D and Wang D (2021) Non-coding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential, Seminars in Cell & Developmental Biology, 10.1016/j.semcdb.2021.07.007, 118, (150-162), Online publication date: 1-Oct-2021. Kasai-Brunswick T, Carvalho A and Campos de Carvalho A (2021) Stem cell therapies in cardiac diseases: Current status and future possibilities, World Journal of Stem Cells, 10.4252/wjsc.v13.i9.1231, 13:9, (1231-1247), Online publication date: 26-Sep-2021. Jiang L, Sun X, Deng J, Hu Y and Xu Q (2021) Different Roles of Stem/Progenitor Cells in Vascular Remodeling, Antioxidants & Redox Signaling, 10.1089/ars.2020.8199, 35:3, (192-203), Online publication date: 20-Jul-2021. Chirico N, Van Laake L, Sluijter J, van Mil A and Dierickx P (2021) Cardiac circadian rhythms in time and space: The future is in 4D, Current Opinion in Pharmacology, 10.1016/j.coph.2020.11.006, 57, (49-59), Online publication date: 1-Apr-2021. Correia M, Bernardes de Jesus B and Nóbrega-Pereira S (2021) Novel Insights Linking lncRNAs and Metabolism With Implications for Cardiac Regeneration, Frontiers in Physiology, 10.3389/fphys.2021.586927, 12 Weinberger F and Eschenhagen T (2021) Cardiac Regeneration: New Hope for an Old Dream, Annual Review of Physiology, 10.1146/annurev-physiol-031120-103629, 83:1, (59-81), Online publication date: 10-Feb-2021. Peng H, Shindo K, Donahue R and Abdel-Latif A (2021) Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair, International Journal of Molecular Sciences, 10.3390/ijms22031201, 22:3, (1201) Chiao Y, Dai D, Wessells R and Rabinovitch P (2021) Cardiac aging Handbook of the Biology of Aging, 10.1016/B978-0-12-815962-0.00015-9, (323-344), . Kartha C (2021) Cell Sources of Cardiomyocytes for Heart Repair Cardiomyocytes in Health and Disease, 10.1007/978-3-030-85536-9_18, (279-292), . Deng J, Ni Z, Gu W, Chen Q, Nowak W, Chen T, Issa Bhaloo S, Zhang Z, Hu Y, Zhou B, Zhang L and Xu Q (2020) Single-cell gene profiling and lineage tracing analyses revealed novel mechanisms of endothelial repair by progenitors, Cellular and Molecular Life Sciences, 10.1007/s00018-020-03480-4, 77:24, (5299-5320), Online publication date: 1-Dec-2020. Duddu S, Chakrabarti R, Ghosh A and Shukla P (2020) Hematopoietic Stem Cell Transcription Factors in Cardiovascular Pathology, Frontiers in Genetics, 10.3389/fgene.2020.588602, 11 Kramer F, Martinson A, Papayannopoulou T and Kanter J (2020) Myocardial Infarction Does Not Accelerate Atherosclerosis in a Mouse Model of Type 1 Diabetes, Diabetes, 10.2337/db20-0152, 69:10, (2133-2143), Online publication date: 1-Oct-2020. Sorensen D and van Berlo J (2020) The Role of TGF—β Signaling in Cardiomyocyte Proliferation, Current Heart Failure Reports, 10.1007/s11897-020-00470-2, 17:5, (225-233), Online publication date: 1-Oct-2020. Soliman H and Rossi F (2020) Cardiac fibroblast diversity in health and disease, Matrix Biology, 10.1016/j.matbio.2020.05.003, 91-92, (75-91), Online publication date: 1-Sep-2020. Chen K, Huang Y, Singh R and Wang Z (2020) Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases, Journal of Cellular Physiology, 10.1002/jcp.29554, 235:9, (6257-6267), Online publication date: 1-Sep-2020. He L, Nguyen N, Ardehali R and Zhou B (2020) Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation, Circulation, 142:3, (275-291), Online publication date: 21-Jul-2020. Witman N, Zhou C, Grote Beverborg N, Sahara M and Chien K (2020) Cardiac progenitors and paracrine mediators in cardiogenesis and heart regeneration, Seminars in Cell & Developmental Biology, 10.1016/j.semcdb.2019.10.011, 100, (29-51), Online publication date: 1-Apr-2020. Weinberger F and Eschenhagen T (2020) Heart regeneration: from mouse to human, Current Opinion in Physiology, 10.1016/j.cophys.2019.10.010, 14, (7-12), Online publication date: 1-Apr-2020. Deutsch M, Brunner S, Grabmaier U, David R, Ott I and Huber B (2020) Cardioprotective Potential of Human Endothelial-Colony Forming Cells from Diabetic and Nondiabetic Donors, Cells, 10.3390/cells9030588, 9:3, (588) Bon-Mathier A, Rignault-Clerc S, Bielmann C and Rosenblatt-Velin N (2020) Oxygen as a key regulator of cardiomyocyte proliferation: New results about cell culture conditions!, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 10.1016/j.bbamcr.2019.03.007, 1867:3, (118460), Online publication date: 1-Mar-2020. Soliman H, Paylor B, Scott R, Lemos D, Chang C, Arostegui M, Low M, Lee C, Fiore D, Braghetta P, Pospichalova V, Barkauskas C, Korinek V, Rampazzo A, MacLeod K, Underhill T and Rossi F (2020) Pathogenic Potential of Hic1-Expressing Cardiac Stromal Progenitors, Cell Stem Cell, 10.1016/j.stem.2019.12.008, 26:2, (205-220.e8), Online publication date: 1-Feb-2020. Halver J, Wenzel K, Sendker J, Carrillo García C, Erdelmeier C, Willems E, Mercola M, Symma N, Könemann S, Koch E, Hensel A and Schade D (2019) Crataegus Extract WS®1442 Stimulates Cardiomyogenesis and Angiogenesis From Stem Cells: A Possible New Pharmacology for Hawthorn?, Frontiers in Pharmacology, 10.3389/fphar.2019.01357, 10 Herrero D, Cañón S, Albericio G, Carmona R, Aguilar S, Mañes S and Bernad A (2019) Age-related oxidative stress confines damage-responsive Bmi1+ cells to perivascular regions in the murine adult heart, Redox Biology, 10.1016/j.redox.2019.101156, 22, (101156), Online publication date: 1-Apr-2019. Chien K, Frisén J, Fritsche-Danielson R, Melton D, Murry C and Weissman I (2019) Regenerating the field of cardiovascular cell therapy, Nature Biotechnology, 10.1038/s41587-019-0042-1, 37:3, (232-237), Online publication date: 1-Mar-2019. Lee R (2018) Adult Cardiac Stem Cell Concept and the Process of Science, Circulation, 138:25, (2940-2942), Online publication date: 18-Dec-2018.Related articlesAdult Cardiac Stem Cell Concept and the Process of ScienceRichard T. Lee,Circulation. 2018;138:2940-2942 December 18, 2018Vol 138, Issue 25 Advertisement Article InformationMetrics © 2018 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.https://doi.org/10.1161/CIRCULATIONAHA.118.035273PMID: 30566022 Originally publishedDecember 17, 2018 Keywordsmyocardial infarctionprogenitor cellsregenerationheart failurePDF download Advertisement SubjectsBasic Science ResearchCell TherapyMyocardial InfarctionMyocardial RegenerationStem Cells
Referência(s)